Consensus Celldex Therapeutics, Inc.

Stocks

CLDX

US15117B2025

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 31/10/2026 HKT			5-day change	1st Jan Change
30.10 ^USD	+0.70%		+2.91%	+10.82%

09-23	Top Midday Decliners	MT
09-23	Celldex Therapeutics, Inc. - Special Call

Evolution of the Average Target: Celldex Therapeutics, Inc.

Evolution of the Target Price: Celldex Therapeutics, Inc.

Changes in Analyst Recommendations: Celldex Therapeutics, Inc.

303d647bb0e586dea58df64d2fc0.e_ITiJNtn7tm9ZYdY0c0tT1Wk6joVx8YS1zS0jiM8Q0.CMFGvMQe99gFgddRLwN1_2o_68qHOnt1HxGBlk7_lDkBmkXy8SX97yid8Q~93700bfa06dcfc80d847415d09b47474

Analysts' recommendations: Celldex Therapeutics, Inc.

07-22	Celldex's Phase 3 Barzolvolimab Study in Chronic Spontaneous Urticaria in Focus After Prurigo Nodularis Exit, Morgan Stanley Says	MT
07-22	Morgan Stanley Adjusts PT on Celldex Therapeutics to $40 From $44, Maintains Overweight Rating	MT
06-10	UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating	MT
04-20	Barclays Upgrades Celldex Therapeutics to Overweight From Underweight, Adjusts Price Target to $45 From $24	MT
03-24	Celldex Therapeutics Shares Rise After Wolfe Research Upgrade	MT
03-23	Wolfe Research Upgrades Celldex Therapeutics to Outperform From Peer Perform, PT is $44	MT
02-26	Morgan Stanley Lifts Price Target on Celldex Therapeutics to $44 From $43, Keeps Overweight Rating	MT
11-07	Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria Study	CI
21/10/25	Mizuho Initiates Celldex Therapeutics at Outperform With $48 Price Target	MT
13/10/25	Barclays Initiates Celldex Therapeutics at Underweight With $25 Price Target	MT
09/05/25	UBS Adjusts Price Target on Celldex Therapeutics to $38 From $44, Maintains Buy Rating	MT
28/04/25	Canaccord Genuity Initiates Coverage on Celldex Therapeutics With Buy Rating, $64 Price Target	MT
20/03/25	Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target	MT
07/10/24	Citigroup Initiates Celldex Therapeutics at Buy With $70 Price Target	MT
30/09/24	Goldman Sachs Initiates Coverage on Celldex Therapeutics With Neutral Rating, $45 Price Target	MT
27/09/24	Wolfe Research Downgrades Celldex Therapeutics to Peer Perform From Outperform	MT
26/09/24	Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight After Barzolvolimab Data	MT
26/09/24	Wells Fargo Upgrades Celldex Therapeutics to Overweight From Equalweight	MT
18/06/24	Stifel Initiates Celldex Therapeutics at Buy Rating With $58 Price Target	MT
11/06/24	Wolfe Research Initiates Coverage on Celldex Therapeutics With Outperform Rating, $51 Price Target	MT
20/12/23	TD Cowen Initiates Celldex Therapeutics at Outperform Rating	MT
10/11/23	Wells Fargo Upgrades Celldex Therapeutics to Equalweight From Underweight With $27 Price Target	MT
07/11/23	HC Wainwright Adjusts Price Target on Celldex Therapeutics to $80 From $73, Maintains Buy Rating	MT
22/08/23	Wells Fargo Starts Celldex Therapeutics With Underweight Rating, $21 Price Target	MT
22/08/23	Analyst recommendations: Applovin, BAE Systems, Evercore, Jefferies, Target...

More recommendations

Other Biotechnology & Medical Research

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CELLDEX THERAPEUTICS, INC.					+109.54%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.88%
	IQVIA HOLDINGS INC.					+15.87%
	BEONE MEDICINES AG					+17.86%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+36.99%
	Weighted average by Cap.					+27.57%